GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) Files An 8-K Results of Operations and Financial Condition
Item 9.01 Results of Operations and Financial Condition.

On August 14, 2017, Gemphire Therapeutics Inc. (the “Company”) issued a press release reporting its financial results for the second quarter ended June 30, 2017.The press release is furnished as Exhibit 99.1 and incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the information included in this Current Report on Form 8-K (including Exhibit 99.1) is furnished to Item 9.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

Description

99.1

Press Release dated August 14, 2017 reporting financial results for the second quarter ended June 30, 2017.


Gemphire Therapeutics Inc. Exhibit
EX-99.1 2 gemp-20170814ex991ae9cbe.htm EX-99.1 Gemp_8-K_Ex_99.1 Exhibit 99.1         Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update   Gemcabene Successful in Phase 2 COBALT-1 HoFH Trial Gemcabene Hits Primary Endpoint in Phase 2 ROYAL-1 Hypercholesterolemia Trial LIVONIA,…
To view the full exhibit click here

About GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP)

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.